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Abstract 
 
Combining anti-resorptive and anabolic drugs for osteoporosis may be a useful strategy to 
prevent hip fractures. Previous studies comparing the effects of alendronate and teriparatide 
alone, combined or sequentially using Quantitative Computed Tomography (QCT) in 
postmenopausal women have not distinguished cortical bone mineral density (CBMD) from 
cortical thickness (CTh) effects, nor assessed the distribution and extent of more localised 
changes. In this study a validated bone mapping technique was used to examine the cortical 
and endocortical trabecular changes in the proximal femur resulting from an 18 month course 
of alendronate or teriparatide. Using QCT data from a different clinical trial, the global and 
localised changes seen following a switch to teriparatide after an 18 month alendronate 
treatment or adding teriparatide to the alendronate treatment were compared. 
CTh increased (4.8%, p<0.01) and CBMD decreased (-4.5%, p<0.01) in the teriparatide 
group compared to no significant change in the alendronate group. A large CTh increase 
could be seen for the switch group (2.8%, p<0.01) compared to a significantly smaller 
increase for the add group (1.5%, p<0.01). CBMD decreased significantly for the switch 
group (-3.9%, p<0.01) and was significantly different from no significant change in the add 
group. CTh increases were shown to be significantly greater for the switch group compared 
to the add group at the load bearing regions. 
This study provides new insights into the effects of alendronate and teriparatide combination 
therapies on the cortex of the proximal femur and supports the hypothesis of an increased 
bone remodelling by teriparatide being mitigated by alendronate. 
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1. Introduction 
 
A consensus statement by The National Institutes of Health (NIH) on the prevention, 
diagnosis, and therapy of osteoporosis defines osteoporosis as a skeletal disorder 
characterized by compromised bone strength predisposing to an increased risk of fracture [1]. 
Several drugs have been introduced for the prevention of osteoporotic fragility fractures. 
These include bisphosphonates such as alendronate (ALN) and the selective estrogen receptor 
modulator raloxifene (RLX). Bisphosphonates are antiresorptive agents that inhibit the 
osteoclastic bone destruction, allowing for the continued mineralisation of existing bone 
matrix. Antiresorptive therapies, however, reduce bone remodelling and do not restore or 
regenerate bone architecture. 
Parathyroid hormone (PTH(1-84)), or its 1-34 amino acid terminal recombinant form 
teriparatide (TPTD), are anabolic agents which, when administered once daily, promote the 
formation of new bone and improve its micro-architecture [2, 3, 4]. TPTD increases bone 
remodelling by stimulating both osteoblastic and osteoclastic activity. While remodelling is 
preceded by a prior bone resorption phase, modelling acts without bone resorption and results 
in an increase in bone mass. Modelling occurs throughout life but is less frequent after 
skeletal maturity. The net increase in bone mass by TPTD from DXA studies indicates the 
presence of some degree of modelling [5]. Indeed histomorphological analyses indicate 
significantly more modelling on teriparatide treated patients compared to placebo [6]. Other 
studies indicate that the heterogeneity of mineralization in cortical bone increases in response 
to an increased remodelling by TPTD [7]. 
Conversely ALN has been shown to reduce the rate of bone remodeling by a decreased 
osteoclastic activity [8]. Secondary calcification of the matrix, however, is now prolonged. 
This increases the uniformity and average degree of matrix mineralisation [9, 10]. As 
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suggested in [9] this does not exclude a continued positive balance or mild augmentation of 
bone matrix volume, hence a thickness increase. 
Both antiresorptive drugs and PTH analogues result in an increase in Bone Mineral Density 
(BMD) to varying extents [11, 12, 13]. Due to the development of osteosarcoma in Wistar 
rats treated with extremely high dose PTH 1-34 [14, 15], regulatory agencies limit the use of 
PTH analogues in humans to a 2 year period. While TPTD has proven effects on reducing the 
incidence of vertebral fractures, particularly so for moderate and severe collapse [2], there is 
also interest in the effects the drug has on hip bone structure. However, it is important to bear 
in mind that TPTD has not been shown to prevent hip fracture in adequately powered clinical 
trials. Based on cost and clinical effectiveness, the National Institute for Health and Care 
Excellence (NICE) in the UK recommends ALN as a first treatment option for fracture 
prevention, with RLX as an alternative [16]. Hence, TPTD is only routinely recommended by 
NICE when the osteoporotic patient with multiple (usually vertebral) fractures has not 
responded well to treatment with an antiresorptive agent, or cannot tolerate the alternatives. 
At that point in the treatment pathway, the physician needs to decide whether to either switch 
to or add TPTD to the patients’ current treatment. In clinical practice, the anti-resorptive is 
almost always stopped, but the rationale for this is not entirely clear. Conversely, the effects 
of combining TPTD with an antiresorptive agent are not obvious and need careful study. 
 
The effects of adding versus switching to TPTD after prior treatment with ALN have 
previously been studied by examining aBMD changes from DXA [17] and volumetric Bone 
Mineral Density (vBMD) changes from QCT [18]. These and other studies comparing 
combination therapy with ALN/PTH sequential therapy have yielded subtly different results. 
One clinical consideration is the transient decline in total hip aBMD during the first 6 months 
of single agent TPTD treatment, which occurred in patients pre-treated with ALN [19, 20] 
and was more noticeable in those with a poor treatment response [21]. These studies indicate 
that continuing ALN during the TPTD treatment might mitigate the initial BMD reduction 
which would presumably benefit the patient already at high risk of hip fracture. 
 
While combination PTH 1-84 and ALN treatment resulted in significantly greater hip aBMD 
than single agent PTH 1-84, the single agent strategy increased the volume of the cortical 
compartment, which was not seen in the combination group [22]. However, vBMD decreased 
with the single PTH 1-84 approach, implying by inference that the increase in cortical 
volume was associated with increased porosity. Volumetric BMD remained unchanged with 
combination treatment. Conversely, TPTD in combination with ALN had less efficacy in 
enhancing aBMD compared with single agent TPTD in the study of Finkelstein et al. [11]. 
The study of Ettinger et al. [19] suggested that such TPTD density gains might be blunted by 
prior anti-resorptive treatment; in that study, patients were pre-treated with ALN for 18-36 
months and there was no significant increase in total hip aBMD after switching to TPTD for 
18 months. Cosman et al. found (with a similar drug regime) that aBMD at the hip did 
increase slightly when patients pre-treated with ALN instead continued ALN as a 
combination ALN/TPTD treatment [23], although the difference with a single ALN treatment 
was not significant. 
 
Most of the previous research analysing the cortical bone mineral density, use methods based 
on thresholding or a fixed region from the outer cortex. Changes in the density from such a 
predefined region can then be due to changes in density, thickness or a combination of both. 
The previously reported changes in cortical BMD [18] thus relate more closely to changes in 
the mass of the cortex. In the proposed method, both the thickness and cortical density are 
accurately measured and distinguished from each other, which has been validated from high 
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resolution CT [24, 25, 26]. Furthermore, other studies examined the changes only globally 
and have not examined the location and distribution of the added bone mass, something we 
have now addressed with the present study. 
 
In previous work, a method was presented to map the cortical thickness over the proximal 
femoral surface, using ordinary clinical Computer Tomography (CT) scan data, which was 
shown to be accurate down to a thickness of 0.3 mm [24]. In addition to thickness, also the 
cortical bone mineral density, endocortical trabecular density and cortical mass surface 
density can be measured over the femoral bone surface, and differences highlighted by 
parametric mapping techniques [25, 26]. In this work, we use these techniques to compare the 
effects of an 18 month treatment by ALN versus TPTD by analysing the global cortical 
changes from a previously published clinical trial [27]. We follow that analysis with a study 
on a separate previously published dataset [18] where all the osteoporotic research 
participants had been established on ALN therapy, as per usual clinical practice. In these 
subjects we compare the global and local changes in cortical parameters 18 months after 
switching treatment from ALN to TPTD, versus 18 months after combining ALN with TPTD. 
 
 
2. Materials and Methods 
 
2.1. Data 
 
In this study the Quantitative Computed Tomography (QCT) scans from two distinct clinical 
trials were analysed. All QCT scans were segmented while blinded to the treatment group but 
not the time point. The subsequent cortical measurements are acquired in an automated 
process requiring no further manual processing of the individual scans. 
 
2.1.1 Alendronate vs Teriparatide 
 
For examining the effects of an 18 month treatment of ALN versus TPTD, a dataset used in a 
previously published study [27] was collected. All participants were part of a randomized, 
parallel, double-blind clinical trial and received either teriparatide (20 μg/day) or oral 
alendronate sodium (10 mg/day) for a period of 18 months. All participants were ambulatory, 
5 years or more past menopause, had a BMD T-score between –2.5 and –4.0 at either the 
lumbar spine or femoral neck, and had normal or clinically insignificant abnormal laboratory 
values, including serum calcium, PTH 1-84, 25-hydroxyvitamin D, and alkaline phosphatase. 
The ALN cohort contains 18 subjects with a mean (± standard deviation) age of 62.3 ± 8.3 
years and the TPTD cohort 19 subjects with a mean age of 66.9 ± 7.6 years. The baseline 
characteristics of this dataset are presented in Table 1 which shows no significant differences 
between the two cohorts for any variables. 
Women were excluded if they had prior treatment with PTH or a PTH analogue; treatment 
with bisphosphonates within 12 months, anabolic corticosteroids or calcitriol or vitamin D 
analogues or agonists within 6 months, estrogens or selective estrogen receptor modulators 
within 3 months, or calcitonin within 2 months; therapeutic doses of fluoride; systemic 
corticosteroid use within 1 month or for more than 30 days in the prior year; use of 
anticoagulants within 1 month; history of diseases other than postmenopausal osteoporosis 
that affect bone metabolism; malignant neoplasms within 5 years; carcinoma in situ of the 
uterine cervix within 1 year; nephrolithiasis or urolithiasis within 2 years; abnormal 
uncorrected thyroid function; liver disease or clinical jaundice; impaired renal function; 
alcohol or other drug abuse; or poor medical or psychiatric risk for treatment. Patients with an 
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increased risk of osteosarcoma (i.e., patients with Paget disease of bone, previous skeletal 
exposure to external beam radiotherapy, or previous malignant neoplasm involving the 
skeleton) were also excluded [27]. 
The institutional review board at each clinical site approved the study protocol, which 
followed the principles of the Declaration of Helsinki. Written informed consent was 
obtained from each participant before the start of screening tests. 
 
2.1.2 Switch vs Add 
 
A different dataset was used to examine the effects of adding versus switching to TPTD after 
a previous treatment with ALN. This data resulted from a trial at 11 centres in the United 
States. Patients were treated with ALN (total of 70 mg/week) for at least 18 months. Each 
treatment arm was then randomly divided in two subgroups whereby patients were either 
switched to or given an added treatment of TPTD (20 μg/day) by daily subcutaneous 
injection. QCT scans were taken at the therapy change point (after 18 months ALN) and 
again 18 months later. During that 18 months, one group had continued with ALN and TPTD 
and the other received TPTD alone. For a complete study description we refer the reader to 
[18]. 
The dataset analysed in this work includes the subjects given at least 18 months ALN 
followed by 18 months of TPTD treatment (either alone or in combination). QCT scans were 
analysed at the therapy change point, following the ALN prior treatment, and after the 18 
months TPTD follow-up treatment. Of the 83 subjects where scans were available at both the 
therapy change point and after the follow-up treatment, one subject was rejected due to 
excessive osteophytes and one due to large image artifacts resulting from the presence of 
large metallic implants. This resulted in a dataset which includes 40 subjects in the switch 
group with a mean age of 69.2 ± 8.2 years and 41 subjects in the add group with a mean age 
of 67.4 ± 9.9 years. It includes women of at least 50 years with a prior diagnosis of 
osteoporosis based on areal BMD or fracture history. The full set of baseline characteristics of 
this study is presented in Table 2. The differences between the switch and add groups were 
not significant for any variables. 
Women were excluded if they had a history of hypercalcemia (except for surgically corrected 
hyperparathyroidism) or metabolic bone diseases other than osteoporosis; secondary causes 
of osteoporosis or malignant neoplasms within the past 5 years; active urolithiasis within the 
past 2 years or at high risk for urolithiasis in the opinion of the investigator; active liver 
disease; substantially impaired renal function; history of excessive alcohol consumption; or 
treatment with other bone-active drugs [18]. 
All patients provided written informed consent and the study was approved by the 
institutional review board at each centre. 
 
 
2.2. Cortical measurements 
 
The cortical measurements were performed using Stradwin
1
. The methods incorporated in 
this software have been shown to be able to measure cortical thickness down to 0.3 mm with 
a mean (± SD) error of 0.01 ± 0.58 mm [24]. These methods were later evaluated for their 
ability to measure also the density and mass of the cortex [25, 26]. All volumes are first 
calibrated using a Mindways calibration phantom (Mindways Software Inc. Austin, TX, 
United States) which converts the CT Hounsfield units to corresponding K2HPO4 equivalent 
                                                 
1
 http://mi.eng.cam.ac.uk/~gmt11/software/software.html 
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density values expressed in mg/cm
3
. The bones are segmented using a user interface provided 
in Stradwin to generate a mesh of the outer bone surface. For each point on the mesh, 
samples are subsequently taken in the CT volume along the surface normal thereby extracting 
a profile of the bone density. A blurred cortical model is then fitted to these samples which 
results in an estimation of several cortical parameters. In Figure 1, we see a schematic 
representation of the model fitting process. The blue line represents the real data as sampled 
from the CT image. The red line depicts the model of the cortex described by the cortical 
parameters and the dashed red line is the blurred model. The cortical bone mapping (CBM) 
technique finds the parameters of the model as well as the blur value such that the blurred 
model best fits the real data. This results in a measurement for the cortical thickness (CTh, 
mm), the cortical bone mineral density (CBMD, mg/cm
3
) as well as a measure for the 
endocortical trabecular density (ECTD, mg/cm
3
), which is the trabecular density directly 
adjacent to the cortex. Finally, from the CTh and CBMD, we compute the cortical mass 
surface density (CMSD, mg/cm
2
) as CMSD = 0.1 × CTh × CBMD which represents the mass 
per unit surface area. This measure can be thought of as the total amount of cortical bone (in 
mg) contained within the calculated endosteal and periosteal cortical boundaries beneath a 
given area (in cm
2
) of bone surface.  
By extracting these measurements at every point of the surface mesh, a colour coded map of 
these values can be shown over the entire bone surface. For a detailed description of this 
method we refer the reader to previously published work [24, 25, 26]. A previous study 
already used this technique to assess the cortical thickness and mass changes in response to 
denosumab [28]. That article provides further descriptions on the cortical parameter mapping 
technique in a population based study which is described briefly in the following section. 
 
 
2.3. Statistical analysis 
 
To allow for a longitudinal and population based analysis of the cortical changes, a point 
correspondence has to be found between the surface maps of all bones. Towards this end a 
canonical proximal femur mesh is first constructed and deformably registered onto all surface 
meshes using the in-house developed software tool wxRegSurf
2
. For left femurs, the 
canonical mesh, which is represented as a right femur, was mirrored to allow for the correct 
correspondences. After the registration, for each vertex in the canonical model the closest 
point on the target mesh is found and the corresponding cortical measurement is copied onto 
the canonical shape. In this way, for each new femur the measurements can be related to the 
measurements on corresponding locations of all previous femurs. For 3 subjects in the ALN 
versus TPTD study, one proximal femur was not fully contained in the CT scan and in the 
add versus switch study 9 subjects had an orthopaedic implant. For these subjects only the 
contra-lateral femur was used. For the remaining subjects, the cortical maps were averaged 
over the two to generate a single cortical parameter map for each subject. By examining 
corresponding points between baseline and follow-up we can map the cortical changes over 
the surface of the proximal femur. Since the same canonical femur shape is used for all 
subjects, we can now also derive statistics about the changes throughout the individual 
cohorts, as well as the differences between them. 
For the ALN versus TPTD cohort, the percentage changes of CTh, CBMD, ECTD and 
CMSD with respect to baseline are measured over the proximal femur surface. The global 
changes (average of every point on the canonical surface) are subsequently calculated for 
both cohorts and a two-sample T-test assesses the significance of the difference between the 
                                                 
2
 http://mi.eng.cam.ac.uk/~ahg/wxRegSurf/ 
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two. 
Similarly, in the add versus switch trial, for each of the two cohorts, the cortical changes are 
measured and averaged over the entire surface to assess the global changes for each trial arm. 
T-tests are performed to assess the significances between the add versus switch trial arms of 
all global cortical parameters. 
Besides an analysis of the mean changes globally, the cortical maps allow us to analyse the 
localised changes as well as the significance of the changes for each point on the surface. In 
addition to this analysis of the changes from baseline, we assess the localised average 
differences and the significances of the differences between the add and switch trial arm. 
These statistical analyses on the surface maps are performed using SurfStat [29], a Matlab 
based toolbox for the statistical analysis of univariate and multivariate surface data using 
linear mixed effects models and random field theory. 
 
 
3. Results 
 
3.1 Alendronate vs Teriparatide 
 
The cortical thickness changes for treatment with ALN and TPTD and the significances of the 
differences between them are presented in Table 3. These results show a significant increase 
in CTh (4.8%, p<0.01), decrease in CBMD (-4.5%, p<0.01) and increased ECTD (3.7%, 
p<0.05) for the TPTD group, while ALN does not result in any significant changes. Only the 
changes in CTh and CBMD were statistically significantly different between ALN and TPTD, 
with p=0.026 and p=0.035 respectively. CMSD did not change significantly for either ALN 
or TPTD treatment, nor did the changes differ significantly between the two (Table 3). 
Cortical maps of the ALN and TPTD single treatment are not included. Only few significant 
patches were seen for the ALN group whereas the TPTD single treatment group shows 
largely the same patterns as the TPTD switch group (Figure 2). 
 
3.2 Switch vs Add 
 
The changes of the cortex in response to switching to or adding TPTD after prior treatment 
with ALN are presented in Table 4. We can see significant differences between the switch and 
add group for the CTh, CBMD and CMSD (p=0.025, p<0.001 and p=0.003 respectively). 
While the switch group shows a greater thickening (2.8%, p<0.01) of the cortex compared to 
the add group (1.5%, p<0.01), for the switch group we can see a large and significant 
decrease for the CBMD (-3.9%, p<0.01) and no significant change in the add group. The 
ECTD, increased significantly for both the switch and add group (4.1% and 4.7% 
respectively, p<0.01) with the differences having no statistical significance (p=0.469). The 
switch group, finally, shows a decrease in CMSD (-1.3%, p<0.05) compared to an increase 
for the add group (1.1%, p<0.05). 
Maps of the cortical changes are shown for the switch group in Figure 2 and the add group in 
Figure 3. These indicate large regions with a significant increased CTh for the switch group. 
For the add group, several patches of significant increases are visible which are of combined 
smaller sized region than the switch group. Looking at the differences in CTh change 
between the switch and add groups (Figure 4a), two patches of significant differences can be 
seen. One at the infero-medial junction of the cortex and one at the calcar femorale. These are 
regions subjected to large compressive forces during stance and normal locomotion. In these 
regions, the switch group produced significantly greater increases in CTh than the add group. 
The colour coded maps of the CBMD changes show large significant localised decreases for 
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the switch group only, the differences with the add group being significant over large regions 
(Figure 4b). In contrast, the ECTD maps show large increases for both switch and add group, 
with no statistically significant differences (Figure 4c). 
The cortical maps of the CMSD changes for the switch group show only a region of 
significant decrease at the lateral side of the trochanter (Figure 2d). For the add groups, 
however, several patches of significant CMSD increases can be seen at the attachment sites of 
the psoas major muscle at the lesser trochanter and the quadratus femoris muscle on the inter-
trochanteric crest, which are the muscles applying force in normal locomotion (Figure 3d). 
The map of the significances of the differences between the CMSD changes indicates a large 
region at the lateral side of the trochanter where the CMSD increase of the add group is 
significantly different from a CMSD decrease in the switch group (Figure 4d). This is likely 
due to the large decrease in the switch group at this location (Figure 2d). 
 
 
4. Discussion 
 
The comparison of the cortical changes between ALN and TPTD is broadly in agreement 
with previous studies [11, 27] as well as studies comparing the effects of ALN and TPTD on 
patients with glucocorticoid-induced osteoporosis [12, 13]. In [27], which analysed data 
resulting from the same clinical trial as reported here, femoral neck aBMD produced 
significant increases for both an 18 month TPTD and ALN treatment (3.9% and 3.5% 
respectively) while in contrast to [11] the differences were not significant. In [11], however, 
the treatment period was 30 months with a TPTD dose twice that of [27]. In [27] a greater but 
not significant increase in trabecular BMD was observed with TPTD than with ALN in the 
femoral neck. This is consistent with the global ECTD changes in our analysis (Table 3). 
Furthermore, in the cortical vBMD of the femoral neck, a significant difference between a 
decrease in the TPTD cohort (-1.2%) and an increase in the ALN cohort (7.7%) was 
observed. While this significant difference is consistent with our results, we show a 
significant decrease in CBMD for the TPTD cohort (-4.5%) which was significantly different 
from no significant change in the ALN cohort. A similar trend was seen for the CMSD with a 
0.3% decrease for TPTD and a 0.1% increase for ALN, although these changes were not 
statistically significant. 
The reduction in the CBMD together with an increase in the ECTD by TPTD (Table 2) has 
also been seen previously in different studies. In [30] a TPTD treatment was shown to result 
in a reduced cortical vBMD and increased trabecular and total vBMD. Similarly, in [31] 
significant decreases in cortical vBMD at the femoral neck and inter-trochanter (-1.2% and -
1.5% respectively) were reported after a 72 week once-weekly 56.5 μg TPTD treatment with 
slight, although not significant, increases in total vBMD. Furthermore, CTh was shown to 
increase compared to a decrease with placebo with the differences being statistically 
significant for the femoral neck and shaft region [31]. Care, however, has to be taken in 
comparing the cortical parameters between studies due to the differences in the techniques 
used to extract these measurements. 
 
Partial volume effects and kernel dependent blur inherent to CT scans can make the cortex 
appear either thinner or thicker than it actually is, with converse effects for the CBMD 
measurements. By the deconvolution method implemented in Stradwin, we are able to 
accurately separate the thickness of the cortex from the cortical density. We are thus able to 
measure longitudinal changes of the CTh and CBMD independently as well as the ECTD and 
derived CMSD measurements. This gives us more insight into the bone remodelling effects 
caused by specific treatment types. In particular, the increased CTh and increased ECTD we 
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see in the TPTD group together with a decreased CBMD gives a strong indication of an 
elevated level of bone remodelling. It supports the hypothesis that increased remodelling by 
TPTD increases CTh and trabecular BMD by new bone deposits which is associated with an 
increased porosity as reflected by the decreased CBMD. 
Moreover, by using a deconvolution on the density profiles we are able to measure cortices 
reliably at a sub-voxel level even for cortices as thin a 0.3mm, which is not possible by 
thresholding methods. This allows us to include measurements in our study over the entire 
proximal femur, including regions with a very thin cortex such as the femoral head. 
 
Regarding differences in response to switching to TPTD after a previous ALN treatment 
versus adding TPTD to a continuing ALN treatment, this has previously been evaluated with 
respect to the vBMD changes at the integral, trabecular and peripheral regions by Cosman et 
al. [18]. That study indicated a significant increase of the trabecular vBMD, which was larger 
for the add group than the switch group. In the analysis of Cosman et al., a cortical 
“peripheral” bone compartment is defined by a threshold on the calibrated density values set 
at 1.0 g/cm
3
 as well as including all bone within 3 mm of the periosteal surface. A reported 
“peripheral” BMD increase can then, in the case of a thin cortex, be caused by an increased 
CBMD as well as an increased cortical thickness. For the “peripheral” BMD, the add group 
resulted in a significant increase (1.9%) which was significantly different (p < 0.0001) from a 
decrease in peripheral BMD of the switch group (-2.2%). In our analysis, which uses data 
from the same clinical trial, we separate the CTh from CBMD and from this provide 
measurements of the CMSD which describe the amount of new bone deposits. Reported 
changes in “peripheral” BMD are therefore expected to relate more closely to the CMSD 
changes than the CBMD reported in our study. This is indeed reflected in the results where 
we can see a significant increase in the CMSD for the add group (1.1%) which is 
significantly different from a significant decrease in the switch group (-1.3%). 
While the CMSD is largely in correspondence with the findings for “peripheral” BMD 
described in [18], in the current analysis of the cortex we find a significantly greater increase 
of the CTh for the switch group compared to the add group (Table 4). The reduced CBMD 
and increased CTh of the switch group are in line with the increased remodelling by a 
treatment of TPTD alone which we saw previously in the TPTD single treatment study (Table 
3). Furthermore, the locations of the CTh increases in the switch group correspond to 
previous findings where the increased thickness in response to TPTD was located at the 
highly loaded regions of the proximal femur [32]. 
TPTD has been shown to increase remodeling-based bone formation, and possibly modeling-
based bone formation [33, 6], which in our work is reflected as an increased cortical 
thickness and ECTD and a reduction in CBMD. This effect is greatly reduced when ALN is 
continued with the TPTD treatment. This supports the hypothesis that ALN mitigates the 
increased rate of remodelling induced by TPTD. The underlying mechanism of action, 
however, can only be determined from histology and from this study we can make no 
conclusive statements about this. 
 
Previous studies on cortical bone microarchitecture changes in women treated with TPTD 
measured from HR-pQCT have shown no changes in measured cortical thickness (from 
which pores are disregarded) with either a decreased cortical BMD [34], or an increased 
cortical porosity [35]. In striking contrast, micro-CT and histomorphometric analyses indicate 
no change in cortical porosity, while increasing cortical width in osteoporotic women treated 
with Teriparatide [36, 37], though it must be noted that sampling issues relating to intra-site 
variability predominate when trying to make assumptions about longitudinal changes on 
pieces of bone removed from patients. These discrepancies in definitions of porosity and 
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width/thickness could be explained by the resolution of the modalities and highlight the 
importance of interpreting the cortical changes in the context of the modality in use. 
 
The relative low resolution of clinical CT scans limits us from measuring detailed changes in 
endocortical structures and in some situations makes it impossible to distinguish trabecular 
bone from cortical bone. The endocortex is a compartment where new bone formation, 
sometimes incorporating new endocortical pores, is commonly seen histologically with 
teriparatide. This effect inevitably changes (even at the histological level) where one would 
draw an endocortical boundary. Figure 5 depicts this at a simulated histological resolution 
(top panel, where new bone formed by teriparatide is shown in green). The lower two panels 
indicate what this process looks like to our cortical parameter measurements, with the first 
row of images before treatment (Baseline) and second row after teriparatide (Follow-up). At 
baseline, our sampling profile passes through a thin cortex at A, but by follow-up a nearby 
trabecula has been joined to the endocortex, in the process creating a pore. The model in 
profile A shows how these effects lead to a decrease in measured cortical BMD at this 
sampling point and an increase in cortical thickness, but without any change in the 
endocortical trabecular density. The model in profile B shows a slightly different effect where 
new trabecular bone now meets the cortex and has been sampled straight through; including 
cortex, newly incorporated pores and the new trabecular tissue. Here the thickness increases 
modestly, the density is unchanged, and the endocortical trabecular density value has 
increased. Although speculative, we suspect that a mixture of both these types of changes 
may account for our finding an increased cortial thickness and endocortical trabecular density 
as well as the decreased cortical BMD in the proximal femora. 
 
Histomorphometry has shown that TPTD treatment results in an increased hetrogeniety [7], 
also when preceded by an antiresorptive [38]. Low mineralised endocortical or preosteal bone 
matrix might affect the cortical measurements in a way that is difficult to predict. Similar to 
the effects resulting from corticalised trabecular bone described above, these changes might 
be measured as either an increased thickness with a decreased CBMD, or the change is 
predominantly described by an increased ECTD. Again, both these two effects are seen in the 
TPTD treatment groups. 
 
Histological studies describe an increased mean degree of mineralisation [9] and decreased 
porosity [10] in ALN treated patients, which can be explained by a continued secondary 
mineralisation or the infilling of the haversian canals. In our study, CBMD with alendronate 
did not increase (instead trending downwards), but a subset of only 18 subjects may not 
provide sufficient statistical power to examine this in detail. 
 
Some limitations of this study should be noted. Although the follow-up QCT scans were 
taken after an 18 month TPTD treatment, improvements in BMD at the proximal femur by 
TPTD, however, occur predominantly beyond the 18 month period [11]. In [39], TPTD 
treatment after ALN treatment resulted in a large and significant decrease in total hip aBMD 
and femoral neck aBMD after the first 6 months (-1.2% and -1.8% respectively). Areal BMD 
measurements subsequently steadily increased towards the 18 month time point, although 
these increases were not significant. In the following 6 months, aBMD increased even more 
rapidly, whereby at the 24 month time point total hip aBMD was increased by 2.1% and the 
femoral neck by 3.4% compared to baseline (both p<0.001). 
 
The model used in this analysis is a simplified model of the cortex. It included only the 
periosteal bone location, the cortical thickness and a cortical, trabecular and soft tissue 
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density. At this resolution, our technique is limited by any subtle changes in the transitional 
zone at the endocortex, as demonstrated in Figure 1. A low density matrix at the endocortical 
surface might affect the measurements somewhat. However, the changes were measured in an 
18 month time frame while primary mineralisation occurs in only a few months. The trends 
seen in this study therefore include many cycles of remodelling. There might still be newly 
laid matrix from more recent deposits but that only slightly affects the general trend in 
cortical changes seen in this 18 month study. 
However, recent studies in ewes, which have a remodeling activity close to humans, show 
that secondary mineralization is complete after a period of 30 months [40]. Thus, the 
secondary mineralisation of newly formed osteoid can still increase the cortical parameters, 
especially upon a continuing treatment with an antiresorptive agent. 
A study continuing the clinical trial described in [22] has shown that ALN treatment results in 
a significant increase in trabecular BMD at the hip compared to a decrease with placebo 
when administered after PTH(1-84) [41]. Stopping the treatment reduces gains made by 
PTH(1-84) which suggests that ALN therapy may sustain gains in BMD from a PTH(1-84) 
treatment. Furthermore, in [42] Continuing ALN after an ALN and TPTD combination 
therapy resulted in continued aBMD increases at both the femoral neck (4.2 ± 1.6%, p<0.001) 
and total hip (4 ± 1.6%, p<0.001). 
 
It should also be noted that the clinical trials from which our data resulted, did not include a 
control group. While we can make a comparison between the treatment types, we cannot 
make any conclusions about the effects of an individual treatment type. 
 
Both ALN and TPTD treatment have been shown to reduce the risk of osteoporotic fractures 
[43, 2]. However, the fracture risk reduction by TPTD on the proximal femur specifically has 
not yet been established in a large enough clinical trial. Such study on the effects of TPTD as 
well as the various proposed combination therapies on the risk of hip fracture is difficult due 
to the large number of participants required. We can, however, relate the secondary effects of 
the pharmaceuticals, such as the cortical measurements presented in this study, to hip fracture 
incidence. This has been briefly investigated in [44] to identify critical regions of the femoral 
cortex in fracture patients but further research is necessary towards this end. 
 
In conclusion, this study analysed the QCT scans acquired in previous clinical trials to 
examine more closely the comparative effects of ALN and TPTD as single treatments or in a 
switch versus add configuration by measuring the cortical changes over the entire bone 
surface of the proximal femur. With new paradigms emerging in the therapeutics of bone 
anabolism, it is important to establish the precise effects of current anabolic strategies with 
teriparatide. Here, we have gained an insight into precisely where cortical parameter changes 
occur in the adult hip, with a suggestion that some of the remodelling-induced thickness 
increases with teriparatide (which might be beneficial at high load bearing areas) are 
mitigated when patients keep taking ALN. How precisely these cortical changes affect the 
risk of hip fracture remains to be examined in more detail. 
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Figure legends 
 
 
Fig. 1. Schematic representation of the cortical measurements. Left shows the line along 
which the QCT values are sampled to generate a density profile. Right depicts the cortical 
model fitted to the density profile with the various cortical parameters. 
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Fig. 2. Cortical changes in response to switching to 18 months of TPTD after a previous ≥18 
months ALN treatment. The grey regions indicate non-significant effects (p>0.05). 
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Fig. 3. Cortical changes in response to adding 18 months of TPTD to a continuing ≥18 
months ALN treatment. The grey regions indicate non-significant effects (p>0.05). 
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Fig. 4. Cortical maps of the differences between adding or switching to TPTD after a prior 
treatment with ALN. The colours express the differences as the mean percentage changes of 
the add group subtracted from the mean percentage changes of the switch group. A positive 
percentage (blue) indicates significantly greater effects of switching compared to adding. A 
negative percentage (yellow) indicates significantly greater effects of adding compared to 
switching. The grey regions indicate non-significant differences (p>0.05). 
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Fig. 5. An illustration of endocortical trabecular bone formation with porosity and their 
possible effects on the cortical measurements at two sampling locations. Synthetic data 
represents baseline cortical bone (light blue) and simulated new bone deposits in response to 
TPTD (green). In this illustration all bone is assumed to contain the same mineral density. 
Baseline and follow-up simulated CT scans represent the smooth and low resolution images 
consistent with CT or HR-pQCT. Profile A shows the incomplete corticalization of trabecular 
bone which leaves a large pore. Here the added trabecular bone is identified as part of the 
cortex, resulting in an increased thickness, while the pore decreases the CBMD measure. 
Profile B indicates a larger region of trabecular bone which leaves several pores. This slightly 
increases cortical thickness and predominantly increases ECTD in the fitted cortical model. 
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Table 1. Baseline characteristics (mean ± standard deviation) of the ALN vs. TPTD study. 
 Alendronate 
(n=18) 
Teriparatide 
(n=19) 
Age (years) 62.3 ± 8.3 66.9 ± 7.6 
Weight (kg) 63.0 ± 12.8 63.0 ± 11.1 
Height (cm) 156.1 ± 6.2 155.8 ± 6.6 
T-score femoral neck -2.0 ± 1.0* -2.2 ± 0.7 
T-score total hip -1.9 ± 1.0* -1.6 ± 0.6 
Mean CTh (mm) 1.3 ± 0.1 1.3 ± 0.1 
Mean CBMD (mg/cm
3
) 928.8 ± 57.6 941.7 ± 28.0 
Mean ECTD (mg/cm
3
) 120.0 ± 29.7 116.1 ± 26.0 
Mean CMSD (mg/cm
2
) 121.8 ± 13.7 125.5 ± 12.1 
* Mean, standard deviation and significances of differences were derived from n=16 subjects 
in the alendronate cohort since for two subjects BMD T-score data was not available. 
 
 
Table 2. Baseline characteristics (mean ± standard deviation) of the switch versus add study. 
 Switch (n=40) Add (n=41) 
Age (years) 69.2 ± 8.2 67.4 ± 9.9 
Weight (kg) 62.1 ± 9.1 63.3 ± 12.1 
Height (cm) 159.9 ± 5.9 159.3 ± 5.9 
Prior treatment duration (months) 54.1 ± 23.8 47.7 ± 22.7 
T-score femoral neck -2.4 ± 0.7 -2.3 ± 0.8 
T-score total hip -2.1 ± 0.8 -2.0 ± 0.9 
Mean CTh (mm) 1.3 ± 0.1 1.3 ± 0.1 
Mean CBMD (mg/cm
3
) 916.1 ± 44.9 929.7 ± 46.6 
Mean ECTD (mg/cm
3
) 101.2 ± 23.2 108.1 ± 29.6 
Mean CMSD (mg/cm
2
) 123.4 ± 15.4 125.0 ± 16.9 
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Table 3: Changes in the cortex in response to ALN or TPTD treatment expressed in mean 
(95% CI) percentage changes from baseline as well as the significances of the differences 
between the ALN and TPTD groups (p-value). 
 alendronate (ALN) teriparatide (TPTD) p-value 
CTh 1.4 (-0.5 to 3.4) 4.8 (2.7 to 6.8)
‡
 0.026 
CBMD -1.2 (-3.1 to 0.6) -4.5 (-6.7 to -2.2)
‡
 0.035 
ECTD -0.2 (-3.6 to 3.1) 3.7 (0.3 to 7.1)
†
 0.117 
CMSD 0.1 (-1.7 to 1.9) -0.3 (-2.1 to 1.5) 0.763 
†
significant change from baseline where p<0.05; 
‡
significant change from baseline where 
p<0.01. 
 
 
Table 4: Changes of the cortex in response to switching to or adding TPTD after prior 
treatment with ALN expressed in mean (95% CI) percentage changes from baseline as well as 
the significances of the differences between the switch and add groups (p-value). 
 switch add p-value 
CTh 2.8 (2.0 to 3.6)
‡
  1.5 (0.7 to 2.3)
‡
 0.025 
CBMD -3.9 (-5.1 to -2.7)
‡
 -0.3 (-1.0 to 0.5) <0.001 
ECTD 4.1 (2.2 to 6.0)
‡
 4.7 (3.1 to 6.3)
‡
 0.469 
CMSD -1.3 (-2.6 to -0.1)
†
 1.1 (0.1 to 2.0)
†
 0.003 
†
significant change from baseline where p<0.05; 
‡
significant change from baseline where 
p<0.01. 
 
